Weekly Research Analysts’ Ratings Updates for AVEO Pharmaceuticals (AVEO)

Several brokerages have updated their recommendations and price targets on shares of AVEO Pharmaceuticals (NASDAQ: AVEO) in the last few weeks:

  • 1/24/2018 – AVEO Pharmaceuticals was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 1/16/2018 – AVEO Pharmaceuticals had its “buy” rating reaffirmed by analysts at B. Riley. They now have a $5.00 price target on the stock.
  • 1/9/2018 – AVEO Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “AVEO is heavily dependent on partnerships for pipeline development and funds. If any of the company’s partners fails to receive regulatory approvals or terminates a deal, AVEO’s future prospects would be severely hampered. Moreover, the company has suffered a string of pipeline setbacks in the past which may have an adverse impact on the stock. Additionally, the company’s targeted RCC space is highly crowded with presence of big players in the area, which is another matter of concern for the company. However, the company got a huge boost with the approval of Fotivda in Europe for first-line treatment of advanced renal cell carcinoma. It is the first approved product in AVEO’s portfolio. Shares of the company have outperformed the industry so far this year. Estimates have remained stable ahead of the Q4 earnings results. The company has a mixed record of earnings surprises in recent quarters.”
  • 1/9/2018 – AVEO Pharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 12/6/2017 – AVEO Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “AVEO reported mixed Q3 results with earnings beating estimates while revenue missing the same. AVEO is heavily dependent on partnerships for pipeline development and funds. If any of the company’s partners fails to receive regulatory approvals or terminates a deal, AVEO’s future prospects would be severely hampered. Moreover, the company has suffered a string of pipeline setbacks in the past which may have an adverse impact on the stock. Additionally, the company’s targeted renal cell carcinoma (RCC) space is highly crowded with presence of big players in the area, which is another matter of concern for the company. However, the company got a huge boost with the approval of Fotivda in Europe for first-line treatment of advanced renal cell carcinoma. It is the first approved product in AVEO’s portfolio. Shares of the company have outperformed the industry so far this year.”

AVEO Pharmaceuticals, Inc. (NASDAQ AVEO) traded up $0.01 on Monday, reaching $3.03. 693,016 shares of the company’s stock were exchanged, compared to its average volume of 1,629,369. AVEO Pharmaceuticals, Inc. has a 1 year low of $0.50 and a 1 year high of $4.24. The company has a debt-to-equity ratio of -0.32, a current ratio of 2.33 and a quick ratio of 2.33. The firm has a market capitalization of $359.06, a P/E ratio of -4.27 and a beta of 1.14.

AVEO Pharmaceuticals (NASDAQ:AVEO) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.03. analysts forecast that AVEO Pharmaceuticals, Inc. will post -0.66 earnings per share for the current fiscal year.

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Receive News & Ratings for AVEO Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply